David Ricks, the chair and CEO of Eli Lilly and Company, and Fatima Cody Stanford, M.D., an obesity medicine physician at Massachusetts General Hospital/Harvard Medical School, talk through the groundbreaking role of GLP-1 medications in transforming the treatment of obesity, and how they might reshape the future of health care, in this interview with Andrew Ross Sorkin at the 2024 New York Times DealBook Summit.